Reduction of Ventricular Hypertrophy and Fibrosis in Spontaneously Hypertensive Rats by L-Arginine

Huai-Ren Chang；Chia-Yen Wu；Yung-Hsiang Hsu；Hsing-I Chen

L-arginin ； cyclic GMP ； nitric oxide ； cardiomyocytes ； ventricular hypertrophy ； fibrosis

The Chinese Journal of Physiology

48卷1期（2005 / 03 / 01）

15 - 22

英文

The purpose of this experiment was to explore long-term L-arginine administration on ventricular hypertrophy and cardiac fibrosis in spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto (WKY) rats. Twenty-four rats of each strain at eight wks of age were divided into two groups-one receiving L-arginine and the other vehicle for twelve wks. Arterial pressure (AP) and heart rate were monitored. At 20 wks of age, the rats’ rings of thoracic aorta were isolated to record isometric tension. The study measured left ventricular weight (LVW), body weight (BW), left ventricular (LV) contents of cGMP, and collagen volume fraction (LVCVF). Histological examination of the LV tissue determined changes in cardiomyocytes. Administration of L-arginine did not alter the AP change in SHR, but reduced the AP in WKY after six wks. Our results showed a significantly higher LVW/BW ratio and LVCVF in vehicle-treated SHR compared to levels in corresponding WKY, whereas, the LV cGMP and nitrite/nitrate measurements were higher in vehicle-treated WKY than in SHR. L-arginine treatment decreased LVW/BW ratio and LVCVF, while increasing the levels of LV cGMP and nitrite/ nitrate only in SHR, consistent with histopathological examinations that showed L-arginine prevented cardiomyocytes from thickness and hypertrophy. Our results suggested that the mechanism of reduction in ventricular hypertrophy and fibrosis following long-term L-arginine administration in SHR may stem from increased myocardial nitric oxide-cGMP signaling, independent of AP and EDV of thoracic aorta.

1. Arnal, J.F.,el Amrani, A.I.,Chatellier, G.,Menard, J.,Michel, J.B.(1993).Cardiac weight in hypertension induced by nitric oxide synthase blockade.Hypertension,22,380-387.
2. Chang, H.-R.,Lee, R.P.,Wu, C.Y.,Chen, H.I.(2002).Nitric oxide in mesenteric vascular reactivity: a comparison between rats with normotension and hypertension.Clin. Exp. Pharmacol. Physiol.,29,275-280.
3. Chang, H.-R.,Wu, C.Y.,Chen, H.I.(1999).Arterial pressure following chronic blockade of endogenous nitric oxide in normotensive and hypertensive rats.Tzu Chi Med. J.,11,41-50.
4. Chen, H.I.,Hu, C.T.(1997).Endogenous nitric oxide on arterial hemodynamics: a comparison between normotensive and hypertensive rats.Am. J. Physiol.,273,816-823.
5. Chen, P.Y.,Sanders, P.W.(1991).L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats.J. Clin. Invest.,88,1559-1567.
6. Dickhout, J.G.,Lee, R.M.(1998).Blood pressure and heart rate development in young spontaneously hypertensive rats.Am. J. Physiol.,274,794-800.
7. Dinerman, J.L.,Lowenstein, C.J.,Snyder, S.H.(1993).Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease.Circ. Res.,73,217-222.
8. Fagan, J.M.,Rex, S.E.,Hayes-Licitra, S.A.,Waxman, L.(1999).L-Arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension.Biochem. Bioph. Res. Comm.,254,100-103.
9. Frohlich, E.D.(1989).Overview of hemodynamic and non-hemodynamic factors associated with left ventricular hypertrophy.J. Mol. Cell Cardiol.,21(suppl V),3-10.
10. Green, L.,Wagner, D.,Glogowski, J.,Skipper, P.,Wishnok, J.,Tannenbaum, S.(1982).Analysis of nitrate, nitrite and [15N]nitrite in biological fluids.Anal. Biochem.,126,131-138.
11. Grieve, D.J.,MacCarthy, P.A.,Gall, N.P.,Cave, A.C.,Shah, A.M.(2001).Divergent biological actions of coronary endothelial nitric oxide during progression of cardiac hypertrophy.Hypertension,38,267-273.
12. Hishikawa, K.,Nakaki, T.,Suzuki, H.,Kato, R.,Saruta, T.(1992).L-Arginine as an antihypertensive agent.J. Cardiovasc. Pharmacol.,20,196-197.
13. Hsieh, N.K.,Wang, J.Y.,Liu, J.C.,Lee, W.H.,Chen, H.I.(2004).Structural changes in cerebral arteries following nitric oxide deprivation: a comparison between normotensive and hypertensive rats.Thromb. Haemost.,92,162-170.
14. Hsieh, N.K.,Wang, J.Y.,Liu, J.C.,Wang, S.D.,Chen, H.I.(2004).Nitric oxide inhibition accelerates hypertension and induces perivascular inflammation in rats.Clin. Exp. Pharmacol. Physiol.,31,212-218.
15. Hu, C.T.,Chang, K.C.,Kuo, T.S.,Chen, H.I.(1994).The correlation of cardiac mass with arterial haemodynamics of resistive and capacitive load in rats with normotension and established hypertension.Pflugers Arch.,428,533-541.
16. Hu, C.T.,Chang, K.C.,Wu, C.Y.,Chen, H.I.(1997).Acute effects of nitric oxide blockade with L-NAME on arterial hemodynamics in the rat.Br. J. Pharmacol.,122,1237-1242.
17. Kolpakov, V.,Gordon, D.,Kulik, T.J.(1995).Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells.Circ. Res.,76,305-309.
18. Kristek, F.(1998).Long-term administration of L-arginine did not influence blood pressure, heart rate, cardiac hypertrophy or arterial wall thickness of spontaneously hypertensive rats.Exp. Physiol.,83,595-603.
19. Kuo, J.F.,Davis, C.W.,Tse, J.(1976).Depressed cardiac cyclic GMP-dependent protein kinase in spontaneously hypertensive rats and its further depression by guanethidine.Nature,261,335-336.
20. Li, H.,Forstermann, U.(2000).Nitric oxide in the pathogenesis of vascular disease.J. Pathol.,190,244-254.
21. Lincoln, T.M.,Komalavilas, P.,Cornwell, T.L.(1994).Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase.Hypertension,23(part II),1141-1147.
22. Masters, B.S.,Ignarro(edited)(2000).Nitric Oxide, Biology and Pathobiology.LJ:San Diego, Academic Press.
23. Matsuoka, H.,Nakata, M.,Kohno, K.,Koga, Y.,Nomura, G.,Toshima H.,Imaizumi, T.(1996).Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats.Hypertension,27,14-18.
24. Moncada, S.,Higgs, A.(1993).The L-arginine-nitric oxide pathway.N. Engl. J. Med.,329,2002-2012.
25. Moncada, S.,Radomski, M.W.,Palmer, R.M.J.(1988).Endothelium-derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function.Biochem. Pharmacol.,37,2495-2501.
26. Morgan, H.E.,Baker, K.M.(1991).Cardiac hypertrophy: mechanical, neural and endocrine dependence.Circulation,83,13-25.
27. Nakaki, T.,Hishikawa, K.,Suzuki, H.,Saruta, T.,Kato, R.(1990).L-Arginine-induced hypotension.Lancet,336,696.
28. Numaguchi, K.,Egashira, K.,Takemoto, M.,Kadokami, T.,Shimokawa, H.,Sueishi, K.,Takeshita A.(1995).Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats.Hypertension,26(part I),957-962.
29. Palmer, R.M.,Ashton, D.S.,Moncada, S.(1988).Vascular endothelial cells synthesize nitric oxide from L-arginine.Nature,333,664-666.
30. Rossi, M.A.,Ramos, S.G.,Prado, C.M.(2003).Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodeling in the absence of hypertrophy.J. Hypertens.,21,993-1001.
31. Schmidt, H.H.,Nau, H.,Wittfoht, W.,Gerlach J.,Prescher, K.E.,Klein, M.M.,Niroomand, F.,Bohme, E.(1988).Arginine is a physiological precursor of endothelium-derived nitric oxide.Eur. J. Pharmacol.,154,213-216.
32. Schultz, R.,Nava, E.,Moncada, S.(1992).Induction and potential biological relevance of a Ca(superscript 2+)-indepdent nitric oxide synthase in the myocardium.Br. J. Pharmacol.,105,575-580.
33. Sladek, T.,Gerova, M.,Znojil, V.,Devat, L.(1996).Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase.Physiol. Res.,45,335-338.
34. Stier, C.T.,Sim, G.J.,Levine, S.(1991).Dietary arginine fails to protect against cerebrovascular damage in stroke-prone hypertensive rats.Brain Res.,549,354-356.
35. Susic, D.,Francischetti, A.,Frohlich, E.D.(1999).Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats.Hypertension,33(part II),451-455.
36. Tobian, L.,Hanlon, S.(1990).High sodium chloride diets injury arteries and raise mortality without changing blood pressure.Hypertension,15,900-903.
37. Ursell, P.C.,Mayes, M.(1995).Anatomic distribution of nitric oxide synthase in the heart.Int. J. Cardiol.,50,217-223.
38. Yu, H.C.,Burrell, L.M.,Black, M.J.,Wu, L.L.,Dilley, R.J.,Cooper, M.E.,Johnston, C.I.(1998).Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats.Circulation,98,2621-2628.

1. Chen, Hsing I(2012).Hemodynamic Mechanism of Ventricular Hypertrophy in Hypertension.中國生理學雜誌,55(6),369-379.
2. Wu, Chia-Yen,Wang, David,Kao, Shang-Jyh,Hsu, Yung-Hsiang,Hsieh, Nan-Kuang,Chen, Hsing I,Chang, Huai-Ren(2007).Nitric Oxide in the Cardiovascular and Pulmonary Circulation - A Brief Review of Literatures and Historical Landmarks.Chinese Journal of Physiology,50(2),43-50.
3. Zemančíková, Anna,Török, Jozef(2016).Agmatine Modulation of Noradrenergic Neurotransmission in Isolated Rat Blood Vessels.中國生理學雜誌,59(3),131-138.